Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

629 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rap1b facilitates NK cell functions via IQGAP1-mediated signalosomes.
Awasthi A, Samarakoon A, Chu H, Kamalakannan R, Quilliam LA, Chrzanowska-Wodnicka M, White GC 2nd, Malarkannan S. Awasthi A, et al. J Exp Med. 2010 Aug 30;207(9):1923-38. doi: 10.1084/jem.20100040. Epub 2010 Aug 23. J Exp Med. 2010. PMID: 20733035 Free PMC article.
IQGAP1: a regulator of intracellular spacetime relativity.
Malarkannan S, Awasthi A, Rajasekaran K, Kumar P, Schuldt KM, Bartoszek A, Manoharan N, Goldner NK, Umhoefer CM, Thakar MS. Malarkannan S, et al. Among authors: awasthi a. J Immunol. 2012 Mar 1;188(5):2057-63. doi: 10.4049/jimmunol.1102439. J Immunol. 2012. PMID: 22345702 Free PMC article. Review.
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A, Ayello J, Van de Ven C, Elmacken M, Sabulski A, Barth MJ, Czuczman MS, Islam H, Klein C, Cairo MS. Awasthi A, et al. Br J Haematol. 2015 Dec;171(5):763-75. doi: 10.1111/bjh.13764. Epub 2015 Oct 16. Br J Haematol. 2015. PMID: 26471982 Free article.
A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.
Awasthi A, Rolland DCM, Ayello J, van de Ven C, Basrur V, Conlon K, Fermin D, Barth MJ, Klein C, Elenitoba-Johnson KSJ, Lim MS, Cairo MS. Awasthi A, et al. Oncotarget. 2017 Dec 9;8(69):113895-113909. doi: 10.18632/oncotarget.23040. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371955 Free PMC article.
Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL.
Chu Y, Awasthi A, Lee S, Edani D, Yin C, Hochberg J, Shah T, Chung TH, Ayello J, van de Ven C, Klein C, Lee D, Cairo MS. Chu Y, et al. Among authors: awasthi a. Oncotarget. 2020 Aug 11;11(32):3035-3047. doi: 10.18632/oncotarget.27691. eCollection 2020 Aug 11. Oncotarget. 2020. PMID: 32850008 Free PMC article.
629 results